PriceTargets.com logo

M.D.C. - MDC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $27.67
  • Forecasted Upside: -14.77 %
  • Number of Analysts: 4
  • Breakdown:
  • 2 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$32.46 As of 12/2/2022 10:00 PM ET
▼ -0.36 (-1.10%)

This chart shows the closing price for MDC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New M.D.C. Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDC

Analyst Price Target is $27.67
▼ -14.77% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for M.D.C. in the last 3 months. The average price target is $27.67, with a high forecast of $28.00 and a low forecast of $27.00. The average price target represents a -14.77% upside from the last price of $32.46.

This chart shows the closing price for MDC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in M.D.C.. This rating has held steady since March 2022, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 3 sell ratings
Ratings as of
6/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 3 sell ratings
Ratings as of
9/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 3 sell ratings
Ratings as of
12/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 3 sell ratings
Ratings as of
3/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
9/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
11/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
12/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/22/2022JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$27.00 ➝ $28.00Low
11/4/2022WedbushLower Target$28.00Low
11/3/2022JPMorgan Chase & Co.Lower TargetNeutral$31.50 ➝ $27.00Low
10/21/2022Raymond JamesDowngradeStrong-Buy ➝ Market PerformLow
7/12/2022JPMorgan Chase & Co.Lower TargetNeutral$40.50 ➝ $38.00Low
6/17/2022Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$27.00High
4/13/2022JPMorgan Chase & Co.Lower TargetNeutral$49.00 ➝ $39.00Medium
3/10/2022JPMorgan Chase & Co.Lower TargetNeutral$66.00 ➝ $49.00Low
2/1/2022WedbushReiterated RatingNeutralMedium
11/8/2021Raymond JamesLower TargetStrong-Buy$79.00 ➝ $77.00Medium
10/14/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$66.00High
8/19/2021Raymond JamesLower TargetStrong-Buy$80.00 ➝ $79.00Low
4/21/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$65.00N/A
4/15/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$65.00High
3/18/2021Bank of AmericaReiterated RatingNeutral ➝ Underperform$63.00High
3/16/2021Wolfe ResearchInitiated CoveragePeer PerformLow
3/12/2021Bank of AmericaDowngradeNeutral ➝ Underperform$63.00Medium
1/25/2021Raymond JamesBoost TargetStrong-Buy$61.00 ➝ $71.00Low
1/5/2021Bank of AmericaDowngradeBuy ➝ NeutralN/A
10/30/2020Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$46.00High
10/26/2020Zelman & AssociatesDowngradeBuy ➝ HoldMedium
10/8/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$50.00 ➝ $67.00High
9/15/2020Bank of AmericaUpgradeNeutral ➝ Buy$57.00High
7/29/2020JPMorgan Chase & Co.Boost TargetNeutral$38.50 ➝ $50.00Medium
7/29/2020Evercore ISIUpgradeIn-Line ➝ Outperform$61.00High
4/9/2020Raymond JamesLower TargetStrong-Buy$52.00 ➝ $35.00High
4/2/2020WedbushLower TargetNeutral$40.00 ➝ $29.00Medium
3/23/2020Bank of AmericaDowngradeHoldHigh
3/18/2020JPMorgan Chase & Co.Lower TargetNeutral$46.50 ➝ $22.00High
1/31/2020Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$39.00 ➝ $42.00High
10/31/2019Zelman & AssociatesDowngradeBuy ➝ HoldMedium
10/31/2019CfraUpgradeHold ➝ BuyLow
9/13/2019WedbushBoost TargetNeutral$35.00 ➝ $41.00High
9/13/2019Raymond JamesUpgradeOutperform ➝ Strong-Buy$42.00 ➝ $49.00High
8/1/2019WedbushBoost TargetNeutral$30.00 ➝ $35.00Low
7/8/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralHigh
5/1/2019WedbushReiterated RatingNeutral$30.00High
11/12/2018WedbushBoost TargetNeutral ➝ Neutral$31.00 ➝ $32.00Low
11/2/2018WedbushLower TargetNeutral ➝ Neutral$34.00 ➝ $31.00Low
10/25/2018Evercore ISIUpgradeOutperform$33.00 ➝ $31.00High
10/11/2018Bank of AmericaSet TargetBuy$34.00Medium
9/21/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$38.00 ➝ $32.00High
8/2/2018WedbushLower TargetNeutral ➝ Neutral$34.00 ➝ $33.00Medium
8/2/2018Bank of AmericaUpgradeUnderperform ➝ Buy$36.00 ➝ $42.00Low
7/13/2018JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$36.00Low
5/8/2018Raymond JamesReiterated RatingOutperform ➝ Buy$35.00 ➝ $39.00Low
5/4/2018Zelman & AssociatesUpgradeHold ➝ BuyLow
5/4/2018WedbushReiterated RatingNeutral$33.00 ➝ $30.00High
5/4/2018UBS GroupReiterated RatingBuy$32.00 ➝ $35.00High
3/19/2018WedbushInitiated CoverageNeutral ➝ Neutral$30.00Low
3/13/2018UBS GroupUpgradeSell ➝ Buy$32.00High
2/13/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$35.00Low
2/13/2018UBS GroupUpgradeMarket Perform ➝ OutperformLow
2/2/2018Bank of AmericaBoost TargetUnderperform ➝ Underperform$31.00 ➝ $34.00Medium
1/17/2018UBS GroupReiterated RatingSell ➝ Sell$30.00 ➝ $32.00Low
(Data available from 12/5/2017 forward)

News Sentiment Rating

0.87 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 71 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2022
  • 22 very positive mentions
  • 113 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2022
  • 16 very positive mentions
  • 57 positive mentions
  • 12 negative mentions
  • 1 very negative mentions
Mentions as of
7/8/2022
  • 29 very positive mentions
  • 80 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2022
  • 22 very positive mentions
  • 58 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2022
  • 8 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2022
  • 10 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
11/5/2022
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/5/2022

Current Sentiment

  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

M.D.C. logo
M.D.C. Holdings, Inc., through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name. The company conducts its homebuilding operations in Arizona, California, Nevada, New Mexico, Oregon, Texas, Washington, Colorado, Idaho, Utah, Maryland, Pennsylvania, Virginia, Tennessee, and Florida. Its financial services operations comprise originating mortgage loans primarily for homebuyers; providing insurance coverage primarily to its homebuilding subsidiaries and subcontractors for homes sold by its homebuilding subsidiaries, and for work performed in completed subdivisions; acting as a re-insurer on the claims; selling third-party personal property and casualty insurance products to homebuyers; and offering title agency services to homebuilding subsidiaries and customers in Colorado, Florida, Maryland, Nevada, and Virginia. M.D.C. Holdings, Inc. was founded in 1972 and is headquartered in Denver, Colorado.
Read More

Today's Range

Now: $32.46
Low: $32.02
High: $32.84

50 Day Range

MA: $30.24
Low: $27.42
High: $32.82

52 Week Range

Now: $32.46
Low: $27.04
High: $56.53

Volume

400,800 shs

Average Volume

637,514 shs

Market Capitalization

$2.31 billion

P/E Ratio

3.69

Dividend Yield

6.16%

Beta

1.38

Frequently Asked Questions

What sell-side analysts currently cover shares of M.D.C.?

The following equities research analysts have issued research reports on M.D.C. in the last twelve months: JPMorgan Chase & Co., Raymond James, StockNews.com, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for MDC.

What is the current price target for M.D.C.?

3 Wall Street analysts have set twelve-month price targets for M.D.C. in the last year. Their average twelve-month price target is $27.67, suggesting a possible downside of 14.8%. JPMorgan Chase & Co. has the highest price target set, predicting MDC will reach $28.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $27.00 for M.D.C. in the next year.
View the latest price targets for MDC.

What is the current consensus analyst rating for M.D.C.?

M.D.C. currently has 2 sell ratings and 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MDC, but not buy more shares or sell existing shares.
View the latest ratings for MDC.

What other companies compete with M.D.C.?

Other companies that are similar to M.D.C. include KB Home, Tri Pointe Homes, Meritage Homes, M/I Homes and Toll Brothers. Learn More about companies similar to M.D.C..

How do I contact M.D.C.'s investor relations team?

M.D.C.'s physical mailing address is 4350 S MONACO STREET SUITE 500, DENVER CO, 80237. The construction company's listed phone number is (303) 773-1100 and its investor relations email address is [email protected] The official website for M.D.C. is www.mdcholdings.com. Learn More about contacing M.D.C. investor relations.